IDEXX Laboratories, Inc.: stock overview

IDXXNASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$704.23

November 13, 2026Market cap $56.1B

DCF calculator

What Ploutos Investor adds for IDEXX Laboratories

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

IDEXX Laboratories had revenue of $4.7B over the last 12 months and net income of $1.2B, a net margin of 25.4%. Revenue grew by 9.7% a year on average over the last 5 years. At $704.23 the shares trade at a P/E of 47.4, against a median of 51.7 over the last 5 fiscal years. It has net debt of $177M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$56.1B
79.62M shares
P/E
47.4
Today47.4
Median51.7
Revenue, 12 months
$4.7B
+9.7% a year over 5 years
Net margin
25.4%
2025: 24.6%, above 89% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+8.4% a year over 2 years

  • 202510-K
    Revenue$4.3B
  • 202410-K
    Revenue$3.9B
  • 202310-K
    Revenue$3.7B

Fiscal years in figures

IDXX's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $46.1B
$56.1B
Enterprise value 
$56.3B
P/E 3-year median: 51.7
47.4
EV / EBIT 
37.4
EV / Revenue 
12.1
P/B 3-year median: 31.1
30.0
FCF yield 3-year median: 2.0%
2.3%
Earnings yield 3-year median: 1.9%
2.1%

Profitability

Gross margin 
62.7%
Operating margin 
32.3%
Net margin 3-year median: 23.1%
25.4%
ROIC 
57.6%
ROIC, 5-year average 
46.3%
ROE 
72.1%

Growth

Revenue, yearly change 
+10.4%
EPS, yearly change 
+22.6%
FCF, yearly change 
+30.8%
Revenue, average a year 
+9.7%
EPS, average a year 
+14.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$198M
Total debt 
$499M
Of which operating leases 
$124M
Net debt 
$177M
Net debt / EBITDA 
0.1x
Interest cover 
43.5x
Current ratio 
1.19

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
2.17%
Total returned 
2.17%
Shares, yearly change 
-2.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

61.8%

Above 73% of the 141 companies in its industry, and 80% of all.

Operating margin

31.6%

Above 92% of the 285 companies in its industry, and 93% of all.

Net margin

24.6%

Above 89% of the 302 companies in its industry, and 87% of all.

ROE

66.0%

Above 96% of the 267 companies in its industry, and 97% of all.

ROA

31.6%

Above 96% of the 313 companies in its industry, and 99% of all.

Revenue growth

10.4%

Above 59% of the 292 companies in its industry, and 64% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
IDEXX LABORATORIES INC /DE
CIK
874716
Exchange
NASDAQ
Industry (SIC)
2835 · In Vitro & In Vivo Diagnostic Substances
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
79.62M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do IDEXX Laboratories's filings show?

These are IDEXX Laboratories's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IDXX

Didn't find what you were looking for?

Ask us
What is IDXX's market cap?

IDEXX Laboratories, Inc.'s market cap is $56.1B, at a price of $704.23 on November 13, 2026 and 79.62M shares.

What is IDXX's P/E?

IDXX's P/E is 47.4, on earnings per share of $14.84 over the last 12 months. The median over the last 5 fiscal years was 51.7.

How much revenue does IDXX have?

IDEXX Laboratories had revenue of $4.7B over the last 12 months. Over the last 5 years it changed by +9.7% a year on average.

Does IDXX pay a dividend?

No. IDEXX Laboratories paid no regular dividend over the last 12 months.

Where do the figures come from?

From IDEXX Laboratories, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.